The website is a joint effort between Merck and The Lancet.
The agency made good on a pledge to expand Bad Ad with a web-based CME course and case studies representing common problems.
Some providers of CME are getting better at complying with accreditation criteria, data show, yet many are still struggling to meet a stricter set of requirements.
Pharma's med-ed cut was its fifth in a row. But other income surged, filling the void as the funding picture for CME continued to even out.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
The estimated cost savings for only 10% of participants changing their practice is somewhere in the million-dollar range, according to a study.
Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&J's SGLT2 inhibitor Invokana.
Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.
What will become of Dollars for Docs after the Sunshine provisions go into effect? We asked Charles Ornstein, who told us what's next for the project.
Gift bans or no, students still connect with drug companies, a study has found.
The med-ed company is buying Amazing Charts, a tie-up the firms say will enable them to deliver customized education to physicians and then assess the patient-level impact.
Only 35% of physicians are aware of the FDA's class-wide safety plan for certain opioids, a survey showed, suggesting an awareness challenge as the plan gets under way.
A new online medical contest is progressing from the diagnosis of minor ailments to cancer screening.
Allergan removed records from its website that had detailed payments made to doctors from the middle of 2010 through first-half 2011.
Those who produce and fund certified medical education acknowledge that conflict of interest is one issue that seems to constantly crop up. But while conflict is inevitable, bias doesn't have to be, they insist in a new video.
Pfizer is changing the way it funds medical education to make smarter use of a shrinking pool of funds and to enhance the impact of activities it supports.
It probably won't have the same ability to tap industry for support, but a new med-ed center at Stanford has some other interesting parallels with the school's CME program.
The ACCME awarded provisional two-year accreditation to Lighthouse Learning, the educational content provider which develops and sells CME curricula without accepting commercial funding.
Corporate logos may still appear in CME commercial support disclosures, ACCME said, after a majority of respondents expressed disapproval of its proposal to ban them.
The drug industry's backing of certified CME fell for a third straight year, as registration fees and other income surged, just-released data from ACCME show.
In a sign of industry's ongoing desire to broaden its CME funding outlook, a couple of recently supported educational programs by Pfizer aim to foster practice-based improvement as they seek to advance the science of CME.
Eli Lilly reported paying $48.1 million to 45,440 physicians and/or 1,827 healthcare organizations during the first quarter, most of it for research and educational programs.
The Florida Department of Health is seeking to sanction a doctor who committed suicide in February, distraught over getting swept up in an off-label promotion sting.
A new report passed by AMA delegates draws ethical boundaries around the use of industry funding for medical education, stopping well short of the all-out ban seen in some previous versions.
The American College of Cardiology (ACC) is eliminating its traditional model for CME-certified satellite symposia at the Annual Scientific Session.
GlaxoSmithKline said Thursday that it paid more than 5,000 US healthcare professionals a total of $56.8 million last year for promotional talks or serving on advisory boards.
Johnson & Johnson reported third-quarter sales of $15 billion, a 0.7% decrease vs. the year-ago quarter, as weaker consumer-product sales weighed on revenue.
Industry support for continuing medical education (CME) has been waning the last two years, but some say the bottom may be in sight.
Yale School of Medicine, which created conflict-of-interest guidelines years ago, has made them binding for physicians in its faculty practice.
Total commercial support of accredited CME fell 17% to $856 million in 2009, according to ACCME's annual report—marking its second straight year of double-digit declines on a percentage basis.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.